December 8, 2015
Source: Oncoimmunology. 2015 Dec 8;5(2):e1117740. eCollection 2016.
Authors: J. Pol, A. Buqué, F. Aranda, N. Bloy, I. Cremer, A. Eggermont, P. Erbs, J. Fučíková, J. Galon, J. M. Limacher, X. Preville, C. Sautès-Fridman, R. Špíšek, L. Zitvogel, G. Kroemer, L. Galluzzi
Oncolytic virotherapy relies on the administration of non-pathogenic viral strains that selectively infect and kill malignant cells while favoring the elicitation of a therapeutically relevant tumor-targeting immune response. During the past few years, great efforts have been dedicated to the development of oncolytic viruses with improved specificity and potency. Such an intense wave of investigation has culminated this year in the regulatory approval by the US Food and Drug Administration (FDA) of a genetically engineered oncolytic viral strain for use in melanoma patients. Here, we summarize recent preclinical and clinical advances in oncolytic virotherapy.